Alogliptin benzoate
CAS: 850649-62-6
Ref. 3D-FA61528
1g | 138,00 € | ||
2g | 194,00 € | ||
5g | 310,00 € | ||
10g | 436,00 € | ||
25g | 647,00 € |
Informação sobre produto
- 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile benzoate
- 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile benzoate
- Alogliptin Benzoate
- Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, benzoate (1:1)
- Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, monobenzoate
- Nesina
- Syr-322
Alogliptin benzoate is an orally active DPP-IV inhibitor that is used for the treatment of type 2 diabetes. Alogliptin benzoate is a prodrug that is hydrolyzed to alogliptin in vivo, which binds to the DPP-IV enzyme and blocks it from degrading the incretin hormones, GLP-1 and GIP. These hormones are released by the ileum after a meal and act on pancreatic beta cells to release insulin. Alogliptin benzoate has been shown to improve glucose levels after a meal, while reducing postprandial glucagon levels, as well as improving insulin sensitivity in patients with type 2 diabetes mellitus. Alogliptin benzoate also reduces bowel disease symptoms such as abdominal pain, diarrhea, and constipation in patients with type 2 diabetes. The analytical method used for measuring alogliptin benzoate concentration in plasma or serum is chromatographic analysis with postpr
Propriedades químicas
Consulta técnica sobre: 3D-FA61528 Alogliptin benzoate
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.